October 21, 2011

Open Letter Urges FDA to Not Delay MSM Access to PrEP

Several nonprofit organizations and coalitions have signed an open letter to the U.S. Food and Drug Administration (FDA) and Gilead Sciences urging them not to delay approval of Truvada, which is made by Gilead, for pre-exposure prophylaxis (PrEP) for men who have sex with men (MSM) and transgender people, according to a statement by the AIDS Vaccine Advocacy Coalition (AVAC). Gilead is seeking FDA approval of Truvada as an HIV prevention in both MSM and heterosexual people; it plans to combine the request for each groups into a single filing. The signers are concerned that reviewing the data for heterosexual people will unnecessarily delay access to PrEP by MSM. The signers include AIDS Action Committee of Massachusetts, AIDS Foundation of Chicago, AIDS Research Consortium of Atlanta, AIDS United, AVAC, Black AIDS Institute, Fenway Health, GMHC, Harlem United, International Rectal Microbicides Advocates, National Minority AIDS Council, Project Inform and San Francisco AIDS Foundation.

To read the open letter, click here.

Search: FDA, PREP, AVAC

Scroll down to comment on this story.